Masimo Corp., a medical monitoring technology company, has filed a federal lawsuit against the U.S. Customs and Border Protection (CBP) for unlawfully allowing Apple Inc. to reactivate the blood-oxygen tracking feature on Apple Watches. Masimo alleges that this feature infringes on its patents and that CBP cleared Apple's iPhone-based blood oxygen solution without proper notice, enabling the importation of Apple Watches with the disputed technology. The legal dispute escalated after the seizure of five Apple Watches at the Port of Chicago in July, which led to further actions involving CBP headquarters in Washington. While Apple received approval from CBP to restore the blood oxygen feature, the U.S. International Trade Commission (ITC) may still object and potentially block the feature's permanent reinstatement. Separately, a German court ruled that Apple cannot advertise the Apple Watch as a "CO2-neutral product," finding the claim misleading and upholding a complaint from environmentalists. This ruling requires Apple to change its advertising practices in Germany regarding the carbon neutrality of the Apple Watch.